Schizophrenia and Disorders with Psychotic Features  >>  risperidone  >>  Phase 2
Welcome,         Profile    Billing    Logout  

20 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
risperidone / Generic mfg.
NCT01363349: Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia

Checkmark P2/3 CLARITY data
Mar 2013 - Mar 2013: P2/3 CLARITY data
Terminated
2b
269
Europe, RoW
CYP-1020, BL-1020, Risperidone
BioLineRx, Ltd.
Schizophrenia, Cognitive Effect on Schizophrenic Patients
03/13
04/13
NCT00921804: Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients

Completed
2a
296
US
AZD 8529, Risperidone, Risperdal, Placebo to match AZD8529, Placebo to match risperidone
AstraZeneca
Schizophrenia
05/10
05/10
NCT00049946: Schizophrenia Study In Adults

Completed
2
231
US
talnetant, risperidone
GlaxoSmithKline
Schizophrenia
04/03
04/03
NCT00639483: Efficacy and Safety of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia

Completed
2
270
Europe, RoW
Celecoxib, Placebo
Pfizer
Schizophrenia
 
01/04
NCT00300963: Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients

Completed
2
275
US
Talnetant
GlaxoSmithKline
Schizophrenia
10/05
10/05
NCT00103727: Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia

Completed
2
282
US
Talnetant, placebo, risperidone
GlaxoSmithKline
Schizophrenia
10/05
10/05
NCT00361166: Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

Completed
2
400
US, RoW
ACP-103
ACADIA Pharmaceuticals Inc.
Schizophrenia
 
03/07
NCT00259870 / 2005-002883-27: SB-773812 Administered In Adults With Schizophrenia

Completed
2
338
US, Europe, RoW
SB-773812, Olanzapine
GlaxoSmithKline
Schizophrenia
 
08/07
NCT00563706: Study Evaluating Vabicaserin in Subjects With Schizophrenia

Completed
2
199
US, Canada
vabicaserin, risperidone, placebo
Pfizer
Schizophrenia
06/08
06/08
NCT00722176: Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020

Completed
2
220
US
BL-1020, BL-1020 10-30 mg, BL-1020 High Dose, risperidone
BioLineRx, Ltd.
Schizophrenia
07/09
12/09
NCT00567710: A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study

Checkmark P2 data
Oct 2012 - Oct 2012: P2 data
Checkmark P2 data
Sep 2012 - Sep 2012: P2 data
Completed
2
360
US
BL - 1020, Placebo, Risperidone
BioLineRx, Ltd.
Schizophrenia
07/09
09/09
NCT00768612: Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia

Withdrawn
2
0
Japan
SCA-136 50mg/day, SCA-136 150 mg/day, SCA-136 300mg/day, Risperidone 4mg/day
Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
07/09
07/09
CONNECT, NCT00439634: Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia

Terminated
2
873
US, Canada
AVE1625, Drinabant, placebo
Sanofi
Schizophrenia
09/09
09/09
NCT00810667 / 2008-001441-26: Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia

Completed
2
124
Europe, RoW
Lu AE58054, Placebo
H. Lundbeck A/S
Schizophrenia, Cognition
01/10
02/10
NCT01175135 / 2010-020764-38: An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia

Completed
2
259
US, Europe, RoW
PF-02545920, Placebo, Risperidone, Risperdal
Pfizer
Schizophrenia
08/11
08/11
NCT01086748: A Study in Schizophrenia Patients

Checkmark P2 data (negative result for H8Y-MC-HBBM (HBBM))
Jul 2012 - Jul 2012: P2 data (negative result for H8Y-MC-HBBM (HBBM))
Completed
2
880
US, RoW
Risperidone, Placebo, LY2140023
Eli Lilly and Company
Schizophrenia
05/12
05/12
NCT01450514 / 2011-004494-81: POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia

Completed
2
7
Europe
Pipamperone, Risperdal, Invega and Xeplion, Placebo
PharmaNeuroBoost N.V.
Chronic Schizophrenia, Schizoaffective Disorder
11/12
12/12
NCT01499563: Study of a Novel Antipsychotic ITI-007 in Schizophrenia

Checkmark Pooled data from '005 and '031 studies in schizophrenia at ASCP 2018 [screenshot]
May 2018 - Jun 2018: Pooled data from '005 and '031 studies in schizophrenia at ASCP 2018 [screenshot]
Checkmark ACNP 2015
Dec 2015 - Dec 2015: ACNP 2015
Checkmark From ITI-007-005 trial for schizophrenia
More
Completed
2
335
US
ITI-007, Placebo, Risperidone
Intra-Cellular Therapies, Inc.
Schizophrenia
08/13
11/13
NCT01623713: Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia

Completed
2
260
RoW
iloperidone, Risperidone
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Schizophrenia, Iloperidone, Efficacy
10/13
11/13
NCT00653406: A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients

Completed
1/2
29
Japan
Risperidone long acting injectable
Janssen Pharmaceutical K.K.
Schizophrenia
 
10/03

Download Options